A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
using redirection mechanisms such as HTTP 301 to automatically refer browsers and crawlers to relocated content. using content management systems which can automatically update links when content within the same site is relocated or automatically replace links with canonical URLs integrating search resources into HTTP 404 pages The detection of broken links may be done manually or automatically. Automated methods include plug-ins for content management systems as well as standalone broken-link checkers such as like Xenu's Link Sleuth. Automatic checking may not detect links that return a soft 404 or links that return a 200 OK response but point to content that has changed.
The variance is infinite. In a real reactor, diffusion will eventually mix the layers so that the tail of the RTD becomes exponential and the variance finite; but laminar flow reactors can have variance greater than 1, the maximum for CTSD reactors.
One of the best-known examples of convergent evolution is the camera eye of cephalopods (such as squid and octopus), vertebrates (including mammals) and cnidarians (such as jellyfish). Their last common ancestor had at most a simple photoreceptive spot, but a range of processes led to the progressive refinement of camera eyes—with one sharp difference: the cephalopod eye is "wired" in the opposite direction, with blood and nerve vessels entering from the back of the retina, rather than the front as in vertebrates. As a result, vertebrates have a blind spot.
Sources: en.wikipedia.org
California, Illinois, and New York passed the first mandatory minimum sentences for drug offenses; Congress followed with the Boggs Act of 1951, creating the first federal mandatory minimums for drugs. The act unified penalties for the Narcotic Drugs Import and Export Act and the Marihuana Tax Act, effectively criminalizing cannabis. Anslinger testified in favor of the inclusion of cannabis, describing a "stepping-stone" path leading from cannabis to harder drugs and crime. First-offense possession of cannabis carried a 2–10-year minimum and a fine of up to $20,000. This marked a change in Congress's approach to mandatory minimums, increasing their number, severity, and the crimes they covered. According to the United States Sentencing Commission, reporting in 2012: "Before 1951, mandatory minimum penalties typically punished offenses concerning treason, murder, piracy, rape, slave trafficking, internal revenue collection, and counterfeiting. Today, the majority of convictions under statutes carrying mandatory minimum penalties relate to controlled substances, firearms, identity theft, and child sex offenses.". In 1961, the Single Convention on Narcotic Drugs became the first of three UN treaties that together form the legal framework for international drug control, and require that domestic drug laws in member countries comply with the conventions. The Single Convention unified existing international drug agreements, and limited possession and use of opiates, cannabis and cocaine to "medicinal and scientific purposes", prohibiting recreational use.
=== Adipose tissue === Increases the release of free fatty acids from adipose tissue. Plasma concentrations of glycerol and nonesterified fatty acids are increased by i.v. infusion of ANP in humans. Activates adipocyte plasma membrane type A guanylyl cyclase receptors NPR-A Increases intracellular cGMP levels that induce the phosphorylation of a hormone-sensitive lipase and perilipin A via the activation of a cGMP-dependent protein kinase-I (cGK-I) Does not modulate cAMP production or PKA activity.
As shown by Lütge, Pikor, and Ludewig (2021), reticular cells in secondary lymphoid organs are not a single homogeneous group of cells, but instead consist of many subtypes of cells defined by their position in the body and expression of cell markers such as podoplanin and ER-TR7.
Sources: en.wikipedia.org
They know it: they made the lawsuit to harm Bolivia." All this set of actions meant that the Peruvian Foreign Ministry had to deliver ten protest notes to its counterpart in Bolivia, since Morales does not respect the rules of conduct that must govern between heads of state. Subsequently, some nationalist sectors in Peru denounced Evo for having claims to carry out a geopolitical project that seeks control of copper, lithium and uranium, as well as an outlet to the sea for Bolivia, to the detriment of Peru. Also, the action of the members from his political party (Movimiento al Socialismo), like the actual presidente of Bolivia (Luis Arce) prompted a formal "vigorous protest" by the Peruvian Foreign Ministry, which accused the Bolivian government of "interference" in Peru's internal affairs, specially during the end of Pedro Castillo government.
==== Black or red ==== Feces can be black due to the presence of red blood cells that have been in the intestines long enough to be broken down by digestive enzymes. This is known as melena, and is typically due to bleeding in the upper digestive tract, such as from a bleeding peptic ulcer. Conditions that can also cause blood in the stool include hemorrhoids, anal fissures, diverticulitis, colon cancer, and ulcerative colitis. The same color change can be observed after consuming foods that contain a substantial proportion of animal blood, such as black pudding or tiết canh. Black feces can also be caused by a number of medications, such as bismuth subsalicylate, activated charcoal, and dietary iron supplements, or foods such as beetroot, black liquorice, or blueberries. Hematochezia is similarly the passage of feces that is bright red due to the presence of undigested blood, either from lower in the digestive tract, or from a more active source in the upper digestive tract. Alcoholism can also provoke abnormalities in the path of blood throughout the body, including the passing of red-black stool. Hemorrhoids can also cause surface staining of red on stools, because as they leave the body the process can compress and burst hemorrhoids near the anus.
In 2018, patisiran was not recommended by NICE in the UK for hereditary transthyretin-related amyloidosis. As of July 2019 further review however is occurring. It was approved for this use in the United States, however. The roles of inotersen and patisiran in cardiac ATTR amyloidosis are still being investigated. In 2021, in a clinical trial using the CRISPR gene-editing technique, several participants had an "80% to 96% drop in TTR levels, on par or better than the average of 81%" who were given patisiran. Vutrisiran was approved by the U.S. Food and Drug Administration (FDA) in June 2022, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
People who intravenously inject black tar heroin are at higher risk of venous sclerosis than those injecting powder heroin. In this condition, the veins narrow and harden which makes repeated injection there nearly impossible. The presence of 6-monoacetylcodeine found in tar heroin has not been tested in humans but has been shown to be toxic alone and more toxic when mixed with mono- or di- acetyl morphine, potentially making tar more toxic than refined diamorphine. Black tar heroin injectors can be at increased risk of life-threatening bacterial infections, in particular necrotizing soft tissue infection. The practice of "skin-popping" or subcutaneous injection predisposes to necrotizing fasciitis or necrotizing cellulitis from Clostridium perfringens, while deep intramuscular injection predisposes to necrotizing myositis. Tar heroin injection can also be associated with Clostridium botulinum infection, causing botulism. Since the final stage of black tar heroin production would kill any spores (a combination of high temperature and strong acid), contamination is likely due to choice of cutting agent. Almost all cases occur in users who inject intramuscularly or subcutaneously, rather than injecting intravenously. Black tar heroin users can also be at increased risk of bone and joint infections that stem from hematogenous seeding or local extension of the skin and soft tissue infections. Any joint can be infected, though previous studies have shown that the knee and hip are most commonly affected in heroin injectors.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.